BCHE and Alzheimer disease: In recent decades, many pharmaceutical platforms have invested hundreds of millions of dollars in the research and development of anti-AD drugs (Cummings et al., 2016; Goldman et al., 2018), but only cholinesterase inhibitors and glutamate receptor blockers can alleviate the symptoms of AD, which still cannot effectively delay the disease progression (Hampel et al., 2018).